These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25124612)

  • 41. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
    van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
    J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
    Gupta NP; Sharma N; Kumar R
    Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
    van Kessel KEM; de Jong JJ; Ziel-van der Made ACJ; Roshani H; Haensel SM; Wolterbeek JH; Boevé ER; Oomens EHGM; van Casteren NJ; Krispin M; Boormans JL; Steyerberg EW; van Criekinge W; Zwarthoff EC
    J Urol; 2020 Jul; 204(1):50-57. PubMed ID: 31985322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical usefulness of the ImmunoCyt urinary test in the follow-up protocol of patients with urothelial neoplasms].
    García Peñalver C; Pérez Barrios A; Leiva Galvis O
    Actas Urol Esp; 2005 Jun; 29(6):535-41. PubMed ID: 16092675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.
    Lotan Y; Elias K; Svatek RS; Bagrodia A; Nuss G; Moran B; Sagalowsky AI
    J Urol; 2009 Jul; 182(1):52-7; discussion 58. PubMed ID: 19450825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.
    Trojan B; Tang A; Chandrapal J; Filleur S; Nelius T
    Ren Fail; 2013; 35(1):72-6. PubMed ID: 23151051
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Determination of NMP-22 as recurrence marker in bladder cancer. Preliminary study].
    Pérez García FJ; Escaf Barmadah S; Fernández Gómez JM; Rodríguez Martínez JJ; Martín Benito JL
    Arch Esp Urol; 2000 May; 53(4):305-12. PubMed ID: 10900760
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
    Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
    Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses.
    Comploj E; Mian C; Ambrosini-Spaltro A; Dechet C; Palermo S; Trenti E; Lodde M; Horninger W; Pycha A
    Cancer Cytopathol; 2013 Jul; 121(7):392-7. PubMed ID: 23495066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NMP22 in transitional cell carcinoma of the urinary bladder.
    Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
    J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Agarwal A
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
    Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?
    Tan WS; Sarpong R; Khetrapal P; Rodney S; Mostafid H; Cresswell J; Hicks J; Rane A; Henderson A; Watson D; Cherian J; Williams N; Brew-Graves C; Feber A; Kelly JD;
    J Urol; 2018 Nov; 200(5):973-980. PubMed ID: 29702097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early results of bladder-cancer screening in a high-risk population of heavy smokers.
    Steiner H; Bergmeister M; Verdorfer I; Granig T; Mikuz G; Bartsch G; Stoehr B; Brunner A
    BJU Int; 2008 Aug; 102(3):291-6. PubMed ID: 18336612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticipatory Positive Urine Tests for Bladder Cancer.
    Gopalakrishna A; Fantony JJ; Longo TA; Owusu R; Foo WC; Dash R; Denton BT; Inman BA
    Ann Surg Oncol; 2017 Jun; 24(6):1747-1753. PubMed ID: 28074325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic accuracy of NMP 22 and urine cytology for detection of transitional cell carcinoma urinary bladder taking cystoscopy as gold standard.
    Sajid MT; Zafar MR; Ahmad H; Ullah S; Mirza ZI; Shahzad K
    Pak J Med Sci; 2020; 36(4):705-710. PubMed ID: 32494260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.